CV Therapeutics Launches 1000 mg Ranexa Tablet

CV Therapeutics, Inc. announced the U.S. Food and Drug Administration approval and U.S. product launch of the 1000 mg tablet of Ranexa (ranolazine extended-release tablets).
CV Therapeutics